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Abstract
Cancer is a genetic disease. Cancer cells contain various mutations, which includes SNPs
to  chromosomal  aberrations.  Together,  these  changes  are  referred  to  as  genome
instability. Genetic instability is one of the common characteristics of colorectal cancer.
In colorectal cancer three major types of genetic instability have been reported. They are
chromosomal  translocations,  microsatellite  instability  (MSI),  and  chromosome
instability (CIN). Microsatellite instability occurs due to variations in DNA mismatch
repair genes, while chromosomal instability is distinguished by major chromosomal
alterations occurring at cell division and usually involves β‐catenin and Adenomatous
polyposis coli protein (APC) mutations. This chapter summarizes the major molecular
mechanisms leading to genomic and microsatellite instability and tumorigenesis.
Keywords: cancer, colorectal cancer, genomic instability, microsatellite instability, mis‐
match repair
1. Introduction
Genomic and microsatellite instability (MSI) play critical roles in both cancer initiation and
progression. This instability can manifest itself genetically on several different levels, ranging
from simple deoxyribonucleic acid (DNA) sequence changes to structural and numerical
abnormalities at the chromosomal level [1]. Since 1990s many researchers reported the presence
of microsatellite instability as a common molecular mechanism in colorectal cancers [2]. Since
then, several studies using numerous methods have characterized MSI molecular subtype [3].
Around 15% of colorectal cancer tumors with a mismatch repair (MMR) system deficiency is
owing to germline, somatic, or epigenetic inactivation [4]. Large number of CRC patients is
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reported to have deficient MMR system [5]. MSI has only slowly been accepted as a clinically
significant aspect of tumor biology even though it is a well‐established molecular marker for
Lynch syndrome patients [6]. The present chapter provides an overview of genomic instability
and molecular basis of the MMR system, the detection of MSI, and the molecular features of
these tumors.
2. Genomic instability
Genetic instability is one of the common characteristics of colorectal cancer. Three major types
of genetic instability have been reported in colorectal cancer [7–10]. Microsatellite instability
occurs due to variations in DNA mismatch repair genes, while chromosomal instability (CIN)
is distinguished by major chromosomal alterations occurring at cell division and usually
involves β‐catenin and Adenomatous polyposis coli protein (APC) mutations [11–13]. Less
prevalent are mutations (germline) in DNA stability genes, including the DNA MMR genes,
MSH6, MSH2, PMS2, and MLH1, which are connected with frameshift mutations and base
pair substitutions in short‐tandem repeat sequences causing microsatellite instability in
HNPCC [14, 15].
Key changes in chromosomal instability in CRC consist of prevalent alterations in chromosome
number and noticeable losses at the molecular level on 5q, 18q, and 17p chromosomes; and
KRAS oncogene mutation. Major genes involved in these alterations are TP53 (17p), Adenom‐
atous polyposis coli protein (APC) (5q), and MADH2/MADH4/DCC (18q) [16, 17]. The loss of
chromosome is linked with instability at the chromosomal and molecular level. In approxi‐
mately 13% of colorectal cancer tumors, MMR deficiency leads to MSI [18]. About 40% of
colorectal cancer cases are distinguished by epigenetic alterations particularly DNA methyl‐
ation, a phenomenon called CpG islands methylator phenotype (CIMP) [19, 20]. In the other
47% of colorectal cancers, CIN affects the tumors by insertions and deletions in chromosomes
[18]. The chromosomal instability group includes cancers with polypoid or aneuploid karyo‐
types, and cancers which have numerous insertions or losses of chromosomal arms. Chromo‐
somal instability results from specific molecular alterations, gene silencing, and also result
from structural defects occurred during cell cycle [21]. In some of the colorectal adenomas it
was observed that the tumor progression starts with chromosome 7 amplification. After this
event, the other specific chromosomal alterations, such as losses on 17p, 8p, 18q, 20q, and 15q
and gains on 20q, 8q, 13, and 7 will generally occur in the colorectal cancers [21–24].
Tumors with microsatellite instability are well known to possess more mutations than other
tumors. Chromosomal instability and microsatellite instability tumors were primarily
considered as equally special, as microsatellite instability tumors usually have constant and
diploid karyotypes [25, 26]. Recent reports have illustrated that the microsatellite instability
and chromosomal instability can arise in the same tumor [27, 28]. Trautmann et al. [29] found
have observed that approximately 50% of hereditary microsatellite instability (MSI‐H) tumors
have similar level of chromosomal aberrations. Although confirmation for similar level of
chromosomal instability can be observed in the majority of hereditary microsatellite instability
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tumors, the specific mutations recognized differed between hereditary microsatellite instabil‐
ity and microsatellite stability tumors [30]. Hereditary microsatellite instability tumors harbor
losses of 15q and 18q and gains of chromosomes 8, 12, and 13, whereas microsatellite stability
tumors have a high level and variable range of chromosomal aberration [29, 31]. In a recent
study by Lassmann et al. [32] in 22 Caucasian colorectal tumors on about 287 sequences found
frequent aberrations in specific regions of chromosomes. This study suggested few candidate
genes with frequent deletion and amplifications in these chromosome regions. A recent exome
analysis of colorectal cancer genomes identified approximately eightfold more nonsynony‐
mous variation in a tumor that displayed microsatellite instability [33].
Genomic instability is a basic feature of tumorigenesis. Three types of genomic instability have
been reported in colon cancer: (i) chromosomal translocations, (ii) microsatellite instability,
and (iii) chromosome instability [34]. The origin of chromosomal instability has been reported
in few subsets of colorectal cancers. Nonetheless, microsatellite instability is renowned to result
from inactivating variations or from unusual methylation of genes in the DNA MMR gene
family. The MMR genes repair nucleotide mismatches arising during the replication [8].
Variations leading to inactivation of MMR system occur in 1–2% of colorectal cancers due to
germline mutations in members of the mismatch repair genes, MSH2, MLH1, MSH6, and
PMS2. Mutations in MMR system are one of the major causes of the familial adenomatous
polyposis syndrome and hereditary nonpolyposis colon cancer syndrome [35].
In microsatellite instability or chromosomal instability the loss of genomic instability occurs
after adenoma formation, but before progression to frank malignancy [36]. However, genomic
instability can be a striking target for anticancer therapies as it is almost omnipresent in
colorectal cancer and is a distinctive feature of cancerous cells. The possibility of targeting
genomic instability for anticolorectal cancer therapy has been proved in in vitro systems [37].
Exploring the basis and roles of genetic and epigenetic instability in colorectal carcinogenesis
has the potential to result in further development of efficient prevention methods and
therapeutics for colorectal cancer [2].
According to the proposed theories, mutations in many pathways have major role in adenoma
carcinoma progression series. In colon cancer, mutations in Adenomatous polyposis coli
protein (APC) as well as the p53 pathways are seen in approximately 95% of the cases [38]. It
has been reported that in approximately 70% of the tumors somatic mutations lead to alteration
of the Ras/Raf pathway. The effect and particular roles of somatic mutations in other genes and
pathways of colorectal cancer are less examined and less understood [36].
Mutational profiling and comparative studies require both tumor and normal tissue samples.
Attaining tumor samples for colorectal cancer studies poses significant technical difficulty. The
signal and noise are indistinguishable when the tumor samples render contamination with
normal tissue. Very few studies have conducted a systematical analysis to resolve the spectrum
of particular mutations in a series of genes in colon cancer tissues and their matching normal
tissues, i.e., a systematic analysis of all genes in the Adenomatous polyposis coli protein (APC)
pathway (Adenomatous polyposis coli protein, axin, and β‐catenin), p53 pathway (BAX, p53,
and MDM2), and RAS pathway (B‐Raf and K‐Ras) in the colorectal cancer tissues [39]. Few
such studies have reported specific variations among the mutations observed in chromosomal
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instability and microsatellite instability tumors. Most of the microsatellite instability tumors
have 30% more mutations in β‐catenin when compared to Adenomatous polyposis coli protein
(APC), while β‐catenin mutations are exceptionally rare in nonmicrosatellite instability
cancers [40]. This is an indirect confirmation recommending that the microsatellite instability
occurs prior to the inactivation of the Adenomatous polyposis coli protein Adenomatous
polyposis coli protein (APC) pathway. Moreover, the spectrum of mutations is different in the
Adenomatous polyposis coli protein (APC) pathway in many of the microsatellite instability
tumors without β‐catenin mutations when compared to nonmicrosatellite instability tumors.
Specially, in simple repeat sequences of microsatellite instability there is an elevated rate of
recurrence of mutations than in the nonmicrosatellite instability cancers [33].
3. Genomic instability in cancer
Genomic instability is a common symptom of most of the tumors and it includes several
genomic alterations ranging from SNPs to large‐scale chromosomal aberrations [41]. This can
be classified into three groups based on the type of genetic changes.
3.1. Nucleotide instability (NIN)
NIN has several genetic variations which includes one or more nucleotide substitutions,
deletions, and insertions. These errors may occur during DNA replication or due to faults in
DNA repair mechanism, such as nucleotide excision repair (NER) and base excision repair
(BER) [42]. These variations in DNA may lead to variations in gene structure and function.
3.2. Chromosomal instability
CIN is one of the common forms of genomic instability, reported in more than 90% of all
cancers. CIN is detected in all stages of cancer [43]. For example, chr 10 is frequently lost in
glioblastomas, which leads to the inactivation of the tumor‐suppressor gene, PTEN. Generally,
CIN refers to changes of chromosomal segments, or entire chromosomes, in terms of their
structure or number, including translocations, additions, deletions, insertions, inversions and
loss of heterozygosity (LOH) [43]. Variation in chromosome numbers is a condition known as
aneuploidy. Chromosome translocation involves the merging of various chromosomes, or of
two distant parts on the same chromosome, which results in the formation of a chimeric
chromosome [44]. In cancer cells, CIN modifies the expression of numerous genes, leading to
a poorer prognosis of patients with MIN or NIN tumors.
3.3. Microsatellite instability
Microsatellites are small tandem repetitive sequences of DNA located throughout the genome.
MIN arises due to the malfunctioning of DNA mismatch repair system. This may result in the
development, shrinkage, deletion, and random insertion of microsatellites [45]. The MMR
system recognizes and attaches to the mismatch, and deletes the erroneous nucleotide and
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maintains the genome integrity. MIN has been recognized in several cancers, including
colorectal, ovarian, lung, endometrial, and gastric [46]. Till now, five MIN markers have been
suggested for disease screening in patients prone to Lynch syndrome. MIN is generally
observed in approximately 15% of all colorectal cancer patients, which contain both hereditary
and sporadic forms. Tumors with MSI are reported to show better prognosis than nonMSI
tumors [46].
4. Molecular basis of the MMR system
Microsatellites are small repetitive sequences dispersed in whole genome, which contain
mono, di, trinucleotide, or tetra nucleotide repeats like (A)n or (CA)n. Most of these repeats are
precisely predisposed to accumulation of mutations, mainly due to the DNA polymerases,
which cannot bind DNA competently at DNA synthesis period. Generally, observed errors in
microsatellites are base–base mismatches, which escape the DNA polymerases proofreading
activity, and insertion–deletion loops, which form DNA hairpins [47]. These unpaired
nucleotides arise when the initial nucleotide and template strand separates and incorrectly
reanneals in a microsatellite. Insertions or deletions in microsatellites situated in exonic regions
causes frameshift mutations, which may lead to truncations of protein [47].
The MMR system is accountable for the recognition and correction of errors that occur in
microsatellites. The major proteins involved in MMR system are MLH1, MSH2, MSH3, MSH6,
and PMS2, and interact as heterodimers. When a mismatch is identified, MsH2 associates with
either MSH6 or MSH3 (forming Mutsα and Mutsβ complexs), and MLH1 couples WITH PMS2,
PMS1, or MLH3 (forms MutLα, MutLβ, or MutLγ complexes) [48]. Muts and a MutL complexes
recognizes mismatches and mutations, and interacts with the replication factor C. Exonuclease
1 and proliferating cell nuclear antigen participate in the excision of mismatches [48]. As a
final step, resynthesis and relegation of the nucleotide strand is done by DNA polymerase δ
and DNA ligase. Variations in the genes responsible for the identification step lead to gathering
of mutations in DNA, which may results in MSI. This has been recognized in various cancers,
including CRC, gastric, endometrial, and few other carcinomas, such as glioblastoma and
lymphomas [2].
5. Detection of MSI
Several techniques that are available to detect tumors with MSI are well established and are
being used as a clinical diagnostic tool. Microsatellite repeats specific to MSI are being detected
by PCR amplification. This can also be determined by comparing the length of nucleotide
repeats in tumor cells and adjacent normal cells. This analysis was initially performed using
polyacrylamide gels and radiolabeled primers; later on, this analysis has been made easier
with fluorescent primers and capillary electrophoresis. In the 1990s, a microsatellite markers
panel, known as the Bethesda panel, with appropriate sensitivity and specificity to diagnose
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MSI CRC has been developed. This panel includes five microsatellite loci: two mononucleoti‐
des (BAT25 and BAT26) and three dinucleotides (D5s346, D2s123, and D17s250) [2].
Few researchers and clinicians have expanded this MSI panel to 10 markers. Three different
MSI groups have been established based on the instability criteria: MSI‐high (MSI‐H),
indicating instability at two or more loci; MSI‐low (MSI‐L), indicating instability at one locus;
and microsatellite stable (MSS), indicating no loci with instability [49]. In most of the patients
MSI‐low cases only show instability for dinucleotide markers, so the analysis of dinucleotides
alone may lead to the misclassification of MSS or MSI‐L colorectal cancer as MSI‐H. In contrast
to this, mononucleotides BAT25 and BAT26 are nearly monomorphic, MSI determination could
be easy using these markers in the absence of normal tissue [50]. Hence, MSI panel has an
appropriate set of markers for MSI detection. These days commercial kits include a majority
of mononucleotide markers with improved sensitivity [51].
MSI can also be detected by gene expression analysis methods. Immunohistochemical analysis
of MMR proteins has become a standard procedure to detect MSI in the diagnosis centers and
as an alternative to the genetic testing of Lynch syndrome [52]. Antibodies against MMR
pathway proteins such as MLH1, MSH2, MSH6, and PMS2 will give a clear awareness about
the mechanism and functioning of the MMR system [15]. Variation in functionality of one or
more MMR genes is diagnostic, and concludes about the gene which is most probable to have
a mutation or which gene got inactivated. Elucidation of the Immunohistochemistry (IHC)
pattern may give more benefit for the dependent expression of heterodimers in the diagnosis
of CRC as described by Vilar and Gruber [2]. They reported that CRCs that are deficient of
expression of MLH1 and PMS2, but gain expression of MSH2 and MSH6, show scarcity in the
expression of MLH1. In this state, deficiency of expression of PMS2 is simply a result of the
inactive MLH1. Whether the absence of MLH1 is initiated by promoter hypermethylation that
leads to inactivation of the gene or a germline mutation that causes Lynch syndrome need
more exploration, but Immunohistochemistry (IHC) results direct the evaluation to
concentrate on MLH1 than the other MMR genes.
6. Conclusions
Genetic instability and microsatellite instability are the most common characteristics of
colorectal cancer. Microsatellite instability is a subclass of CRC, which is reported to show a
clear histopathological and therapeutic profile compared to other molecular subtypes. Various
advanced methods have been developed in the past two decades for the detection of MSI. The
molecular basis of MSI in cancer is still being explored. Recent findings revealed that MSI is
caused due to mutations in genes coding for kinases. Further studies are required to identify
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